These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 14614002)

  • 1. Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days.
    Sun W; Stevenson JP; Gallagher ML; Vaughn D; Hahn SM; Haller DG; Cohen M; Kopit J; Gallant G; O'Dwyer PJ
    Clin Cancer Res; 2003 Nov; 9(14):5221-7. PubMed ID: 14614002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies.
    Advani R; Fisher GA; Lum BL; Jambalos C; Cho CD; Cohen M; Gollerkeri A; Sikic BI
    Clin Cancer Res; 2003 Nov; 9(14):5187-94. PubMed ID: 14613998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumours.
    du Bois A; Jung B; Loehr A; Schaller-Kranz T; Cohen M; Frickhofen N
    Br J Cancer; 2006 Jan; 94(1):79-84. PubMed ID: 16333310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
    Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
    Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.
    Abraham J; Agrawal M; Bakke S; Rutt A; Edgerly M; Balis FM; Widemann B; Davis L; Damle B; Sonnichsen D; Lebwohl D; Bates S; Kotz H; Fojo T
    J Clin Oncol; 2003 May; 21(9):1866-73. PubMed ID: 12721265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.
    Specenier P; Rasschaert M; Van den Brande J; Dyck J; Schrijvers D; Huizing MT; Vermorken JB
    Anticancer Drugs; 2010 Mar; 21(3):306-12. PubMed ID: 20087171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors.
    Mani S; McDaid H; Hamilton A; Hochster H; Cohen MB; Khabelle D; Griffin T; Lebwohl DE; Liebes L; Muggia F; Horwitz SB
    Clin Cancer Res; 2004 Feb; 10(4):1289-98. PubMed ID: 14977827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel.
    Hidalgo M; Aylesworth C; Hammond LA; Britten CD; Weiss G; Stephenson J; Schwartz G; Patnaik A; Smith L; Molpus K; Felton S; Gupta E; Ferrante KJ; Tortora A; Sonnichsen DS; Skillings J; Rowinsky EK
    J Clin Oncol; 2001 May; 19(9):2493-503. PubMed ID: 11331328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days.
    Bilenker JH; Stevenson JP; Gallagher ML; Vaughn D; Cohen MB; O'Dwyer PJ
    Br J Cancer; 2004 Jul; 91(2):213-8. PubMed ID: 15213727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors.
    Ryan DP; Eder JP; Puchlaski T; Seiden MV; Lynch TJ; Fuchs CS; Amrein PC; Sonnichsen D; Supko JG; Clark JW
    Clin Cancer Res; 2004 Apr; 10(7):2222-30. PubMed ID: 15073096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours.
    Kosmas C; Tsavaris NB; Polyzos A; Malamos NA; Katsikas M; Antonopoulos MJ
    Br J Cancer; 2000 Jan; 82(2):300-7. PubMed ID: 10646881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.
    Posey JA; Wang H; Hamilton J; Delgrosso A; Zhang R; Freda T; Zamboni WC
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):182-8. PubMed ID: 15838660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
    Van Den Neste E; de Valeriola D; Kerger J; Bleiberg H; Kusenda Z; Brassinne C; Bartholomeus S; Selleslags J; Hennebert P; Wythouck H; Cazenave I; Lefresne-Soulas F; Piccart M
    Clin Cancer Res; 2000 Jan; 6(1):64-71. PubMed ID: 10656433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies.
    Plummer R; Ghielmini M; Calvert P; Voi M; Renard J; Gallant G; Gupta E; Calvert H; Sessa C
    Clin Cancer Res; 2002 Sep; 8(9):2788-97. PubMed ID: 12231518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.
    Dy GK; Bruzek LM; Croghan GA; Mandrekar S; Erlichman C; Peethambaram P; Pitot HC; Hanson LJ; Reid JM; Furth A; Cheng S; Martell RE; Kaufmann SH; Adjei AA
    Clin Cancer Res; 2005 Mar; 11(5):1877-83. PubMed ID: 15756013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors.
    Bailey HH; Alberti DB; Thomas JP; Mulkerin DL; Binger KA; Gottardis MM; Martell RE; Wilding G
    Clin Cancer Res; 2007 Jun; 13(12):3623-9. PubMed ID: 17510207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors.
    Bahleda R; Sessa C; Del Conte G; Gianni L; Capri G; Varga A; Oprea C; Daglish B; Hospitel M; Soria JC
    Invest New Drugs; 2014 Dec; 32(6):1188-96. PubMed ID: 24898305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I clinical and pharmacokinetic study of fenretinide combined with paclitaxel and cisplatin for refractory solid tumors.
    Otterson GA; Lavelle J; Villalona-Calero MA; Shah M; Wei X; Chan KK; Fischer B; Grever M
    Invest New Drugs; 2005 Dec; 23(6):555-62. PubMed ID: 16034523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies.
    Fishman MN; Garrett CR; Simon GR; Chiappori AA; Lush RM; Dinwoodie WR; Mahany JJ; Dellaportas AM; Cantor A; Gollerki A; Cohen MB; Sullivan DM
    Clin Cancer Res; 2006 Jan; 12(2):523-8. PubMed ID: 16428495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.